Austin, TX May 04, 2021 – Phylloceuticals Ventures is pleased to announce that Curt Cornwell will be taking the role of Senior Advisor with the company. Mr. Cornwell was a Partner with PricewaterhouseCoopers for over twenty years. In his capacity as an Advisory Partner with PwC’s Deals Practice, Curt held key account leadership roles, with significant experience advising clients with their M&A and transformation efforts. He was PwC’s NY Private Equity leader and later Sovereign Investment Fund leader. He has assisted several value-oriented private equity funds in executing large complex deals, linking diligence findings to value creation opportunities. His advice surrounding deals often included carve-out strategy, set up and operational growth options, bolt-on acquisitions, as well as exits.
In his capacity as a Senior Advisor for Phylloceuticals, he will help develop strategies for moving projects into overseas regions, while overseeing fundraising activities for Phylloceutical Ventures and the subsidiaries, clients and affiliates that may be created in the future. "Curt's experience navigating the complexities of international business from his long career at PWC will be of immense value to our team. We see, every day, how severely some areas of the world are affected by no access to needed medicine. These are often areas of the world that need us most, and Curt’s guidance will ensure that our engagement with these regions will be seamless,” says Bill Brydges, CEO of Phylloceuticals.
Phylloceuticals uses their PhAAST platform to help clients, countries and companies achieve supply chain independence by quickly helping them produce needed drugs: monoclonal antibodies, adjuvants, and vaccines up and running, a vision with which Curt Cornwell was immediately intrigued. He says, "From my first meeting with the Phylloceuticals team, my interest was piqued. There are multiple facets to the business that I could appreciate immediately: philanthropy, sustainability, and technological relevance were first, followed closely by the impressive bios of this senior management team. They have lived in the pharma world for decades. Personally, I am interested in helping them achieve their mission of delivering medicine to underserved areas of the world and feel that the momentum they have attained in such a short time will continue at a steep rate using public/private and private investment."
Phylloceuticals is a global technology company dedicated to providing affordable medicine to underserved areas of the world. Founded in 2021, Phylloceuticals is rapidly building a reputation for solving complex technical challenges in the most demanding environments — and allowing needed drugs to be produced locally, with ongoing support from our team.
Phylloceuticals uses a plant-made technology which offers lower overall investment and a much quicker response time for drug development. Drug development and manufacturing happen fast (PhAAST™), empowering underserved areas of the world to gain access to biologics medicines that other areas of the world take for granted. Phylloceuticals is not a CDMO. We are not a biologics or pharma company. Our mission is to nucleate, enable, and help construct companies in these traditionally underserved regions and underserved markets to manufacture biologics with our plant-made technology. We call it PhAAST™ - Pharmaceuticals as a Service Technology.
For more information on Phylloceuticals, please visit http://phylloceuticals.com and connect with Phylloceuticals on LinkedIn.
Susan Stipa, 484.883.8808, McDay|CGLife, mc-day.com